Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes inadequately controlled with metformin monotherapy: VERTIS-Asia

被引：0
|
作者：
Yang, M. [1 ]
Ji, L. [2 ]
Liu, Y. [3 ]
Miao, H. [4 ]
Xie, Y. [5 ]
Wang, W. [1 ]
Mu, Y. [1 ]
Yan, P. [1 ,6 ]
Pan, S.
Lauring, B. [7 ]
Liu, S. [8 ]
Huyck, S. [7 ]
Wang, D. [8 ]
Terra, S. G. [9 ]
机构：
[1] Pfizer China R&D Co, Shanghai, Peoples R China
[2] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[3] Yancheng First Peoples Hosp, Yancheng, Peoples R China
[4] Nanjing Med Univ, Affiliated Hosp 2, Nanjing, Jiangsu, Peoples R China
[5] Pingxiang Peoples Hosp, Pingxiang, Peoples R China
[6] Pfizer Inc, New York, NY USA
[7] Merck & Co Inc, Kenilworth, NJ USA
[8] Merck & Co Inc, Beijing, Peoples R China
[9] Pfizer Inc, Andover, MA USA
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
633
引用
收藏
页码：S307 / S308
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of Ertugliflozin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy in the VERTIS-Asia study
    Yang, Ming
    Ji, Linong
    Liu, Yanmei
    Miao, Heng
    Xie, Yongli
    Wang, Wei
    Mu, Yuting
    Yan, Ping
    Pan, Sharon
    Lauring, Brett
    Liu, Shu
    Huyck, Susan
    Wang, Yinna
    Terra, Steven G.
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34
  • [2] Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
    Ji, Linong
    Liu, Yanmei
    Miao, Heng
    Xie, Yongli
    Yang, Ming
    Wang, Wei
    Mu, Yuting
    Yan, Ping
    Pan, Sharon
    Lauring, Brett
    Liu, Shu
    Huyck, Susan
    Qiu, Yanping
    Terra, Steven G.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1474 - 1482
  • [3] Efficacy and safety of ertugliflozin in patients with type 2 diabetes inadequately controlled with metformin monotherapy: VERTIS MET trial
    Charbonnel, B.
    Pascu, R.
    Frias, J.
    Pall, D.
    Saur, D.
    Darekar, A.
    Huyck, S.
    Shi, H.
    Lauring, B.
    Terra, S.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2017, 60 : S406 - S407
  • [4] Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial
    Hollander, P.
    Liu, J.
    Hill, J.
    Johnson, J.
    Jiang, Z.
    Golm, G.
    Huyck, S.
    Terra, S.
    Mancuso, J. P.
    Engel, S.
    Lauring, B.
    [J]. DIABETOLOGIA, 2017, 60 : S19 - S20
  • [5] Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
    Matthew J. Budoff
    Timothy M. E. Davis
    Alexandra G. Palmer
    Robert Frederich
    David E. Lawrence
    Jie Liu
    Ira Gantz
    Giuseppe Derosa
    [J]. Diabetes Therapy, 2021, 12 : 1279 - 1297
  • [6] Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
    Budoff, Matthew J.
    Davis, Timothy M. E.
    Palmer, Alexandra G.
    Frederich, Robert
    Lawrence, David E.
    Liu, Jie
    Gantz, Ira
    Derosa, Giuseppe
    [J]. DIABETES THERAPY, 2021, 12 (05) : 1279 - 1297
  • [7] Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
    Strojek, Krzysztof
    Pandey, A. Shekhar
    Dell, Vanessa
    Sisson, Melanie
    Wang, Shuai
    Huyck, Susan
    Liu, Jie
    Gantz, Ira
    [J]. DIABETES THERAPY, 2021, 12 (04) : 1175 - 1192
  • [8] Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
    Krzysztof Strojek
    A. Shekhar Pandey
    Vanessa Dell
    Melanie Sisson
    Shuai Wang
    Susan Huyck
    Jie Liu
    Ira Gantz
    [J]. Diabetes Therapy, 2021, 12 : 1175 - 1192
  • [9] Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 104-week VERTIS MET Trial
    Gallo, S.
    Charbonnel, B.
    Goldman, A.
    Shi, H.
    Huyck, S.
    Darekar, A.
    Lauring, B.
    Terra, S. G.
    [J]. DIABETOLOGIA, 2018, 61 : S303 - S304
  • [10] Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial
    Gallo, Silvina
    Charbonnel, Bernard
    Goldman, Allison
    Shi, Harry
    Huyck, Susan
    Darekar, Amanda
    Lauring, Brett
    Terra, Steven G.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 1027 - 1036
12345